Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Active not recruiting 5Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Thoracic 6

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 4Neuroma, Acoustic 1Neurofibromatosis 2 1NSCLC 1Meningioma 1Lymphoma, Large-Cell, Anaplastic 1Granuloma, Plasma Cell 1Ependymoma 1ALK-positive Advanced NSCLC 1ALK+ Advanced NSCLC 1

Interventions

pembrolizumab 244Carboplatin 214Pemetrexed 180Cisplatin 134Paclitaxel 115Nivolumab 102Docetaxel 88osimertinib 85durvalumab 79Specimen Handling 56atezolizumab 55Gemcitabine 53Drug Therapy 53Magnetic Resonance Spectroscopy 50Radiosurgery 49Radiotherapy 48Ipilimumab 41130-nm albumin-bound paclitaxel 39cemiplimab 38Bevacizumab 35tislelizumab 31Cetuximab 30amivantamab 23Taxes 22Blood Specimen Collection 21Platinum Compounds 20Immunotherapy 18Immune Checkpoint Inhibitors 18Radiation 17Erlotinib Hydrochloride 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × brigatinib × 1 year × Clear all
NCT05100069 2026-03-17

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Takeda

Recruiting
500 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05721950 2026-02-18

Brilliant

Takeda

Active not recruiting
154 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04223596 2026-02-04

CUBIK

Fundación GECP

Phase 2 Active not recruiting
33 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05200481 2025-11-17

MP-ALK

Intergroupe Francophone de Cancerologie Thoracique

Phase 2 Active not recruiting
110 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03707938 2025-11-03

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
35 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04227028 2025-09-16

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

City of Hope Medical Center

Phase 1 Active not recruiting
5 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡